검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Autologous CAR-T cells |
Overview Company | Hebei Senlang Biotechnology Inc., Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting specific tumor-associated antigen |
MoA Biomarker | CD19 CAR-T cells can effectively treat high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Toxicology CRS | grade 1-2 |
Clinical Primary efficacy | ORR 80.3% |
Clinical ORR | 80.3% |
Clinical PFS | 9.03 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Autologous CAR-T cells |
Overview Company | Hebei Senlang Biotechnology Inc., Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Leukemia; Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting specific tumor-associated antigen |
MoA Biomarker | CD19 CAR-T cells can effectively treat high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.. The best way to monitor Chimeric Antigen Receptor (CAR)-T cells persistence and expansion in vivo after infusion, and the significance of observed fluctuations over time remains controversial. As living drugs, these therapies do not follow classical … |
Toxicology CRS | grade 1-2 |
Clinical Primary efficacy | ORR 80.3% |
Clinical ORR | 80.3% |
Clinical PFS | 9.03 |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03483103 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교